PLAUR and neoplasm: Despite the cyclic DOTA–AE105 variants (9b) and (11b) exhibit improved uPAR affinity compared to DOTA–AE105 (1b) (Table 1 and Fig S5), we found only minor differences in tumor max uptake values and in tumor-to-organ ratios (Figs. 7, S6, and S7).